B
BIIB icon

Baird’s Biogen BIIB Stock Holding History

Baird’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$1.67M Sell
3,954
-5,721
-59% -$2.25M 0.02% 594
2014
Q4 		$3.28M Buy
9,675
+7,525
+350% +$2.43M 0.04% 437
2014
Q3 		$711K Buy
2,150
+45
+2% +$14.8K 0.01% 749
2014
Q2 		$664K Sell
2,105
-44
-2% -$13.2K 0.01% 769
2014
Q1 		$657K Buy
2,149
+10
+0.5% +$3.17K 0.01% 767
2013
Q4 		$598K Buy
2,139
+132
+7% +$34.1K 0.01% 774
2013
Q3 		$483K Hold
2,007
– – 0.01% 804
2013
Q2 		$432K Buy
+2,007
New +$429K 0.01% 811

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Baird's BIIB Position: Q1 2015 in Review

Baird reduced its Biogen (BIIB) stake by 59% in Q1 2015, selling an estimated $2.25M and leaving 3,954 shares worth $1.67M. The position accounts for 0.02% of the portfolio, ranked #594.

Baird first reported a position in BIIB in Q2 2013 and has held it in 8 quarters since. The position peaked at $3.28M in Q4 2014. 966 funds tracked by Wall St. Rank hold BIIB as of Q1 2015.

  • Baird held 3,954 shares of Biogen worth $1.67M as of Q1 2015.
  • Baird sold 5,721 Biogen shares in Q1 2015, an estimated $2.25M.
  • Biogen made up 0.02% of Baird's portfolio in Q1 2015, its #594 holding.
  • Baird first reported a position in Biogen in Q2 2013 and has held it in 8 quarters since.
  • Baird's Biogen position peaked at $3.28M in Q4 2014.
  • 966 funds tracked by Wall St. Rank held Biogen as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.